RENEE POESNECKER: Open Payments
NPI 1104660448 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,612 in 59 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,612
Food & beverage: $1,611Education: $1
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 13 | $423 |
| Merck Sharp & Dohme LLC | 11 | $271 |
| La Jolla Pharmaceutical Company | 7 | $185 |
| Melinta Therapeutics, LLC | 7 | $163 |
| ViiV Healthcare Company | 4 | $126 |
| Insmed, Inc. | 5 | $107 |
| Theratechnologies Inc. | 4 | $93 |
| Aimmune Therapeutics, Inc. | 2 | $58 |
| ABBVIE INC. | 2 | $54 |
| Shionogi Inc | 1 | $44 |
Products named: Biktarvy, ZERBAXA, Arikayce, XACDURO, Kimyrsa, EGRIFTA, ZEVTERA, PIFELTRO.
Industry payments across VA — which companies pay providers there.
